MVHealth: Timeline of Main Events
2014
Company Formation in the UK: MVHealth is established in the United Kingdom.
Crescendo Prototype: Development of the initial prototype for the Crescendo device.
2015
End-to-End R&D Centre Setup in UK: MVHealth establishes its own research and development facility in the UK.
Tenuto Prototype: Development of the initial prototype for the Tenuto device.
Seed Funding Round: MVHealth raises $1.3m with a pre-money valuation (PMV) of $4.9m.
2016
Crescendo Launch: The Crescendo device is officially launched.
Seed Funding Round: MVHealth raises an additional $718k with a PMV of $6.6m.
2017
Apple iOS App Launch: MVHealth releases its companion application for Apple devices.
Google Android App Launch: The Android version of the MVHealth application is launched.
Poco Prototype: Development begins for the Poco device.
Remote Prototype: Initial development of a remote control device (likely for their products).
TC Disrupt, Pioneers: MVHealth participates in the TechCrunch Disrupt event.
Hardware Club: MVHealth joins the Hardware Club, an exclusive community for hardware startups.
Awards: MVHealth receives Red Dot Design and Virgin Voom Export awards, and is recognized as a Top 100 Startup.
2018
Poco Launch: The Poco device is officially released.
Remote Launch: The remote control device is launched.
Fully-Owned Subsidiary in US: MVHealth establishes a subsidiary in the United States.
Angels Funding Round: MVHealth secures $1.5m in funding with a PMV of $14.1m.
FDA Class II Device Registration: MVHealth achieves FDA Class II medical device registration.
Launched D2C Site: MVHealth begins selling directly to consumers through their own website.
London Mayor's Programme: MVHealth participates in a program supported by the Mayor of London.
Crescendo GPPPD & Tenuto ED Studies Published: Clinical studies demonstrating the effectiveness of Crescendo for Genito-Pelvic Pain Disorders (GPPPD) and Tenuto for Erectile Dysfunction (ED) are published.
Awards: MVHealth receives Management Today, The Drum, Creative Tech, and Clio awards.
2019
Tenuto 2 & Crescendo 2 Prototypes: Development of the next generation devices, Tenuto 2 and Crescendo 2, begins.
Angels Funding Round: MVHealth raises a further $2m with a PMV of $18.9m.
Whitelisted by Meta, Google, Microsoft: MVHealth achieves whitelisting status with major technology platforms.
Upgraded to Sustainable Packaging: The company transitions to more environmentally friendly packaging.
Developed Back Pain Belt for PainCareLabs & Compact Massager for Large Corporate: MVHealth leverages its technology to create products for other companies, including a back pain belt using their malleable technology for Pain Care Labs and a compact massager for an unnamed large corporate.
Awards: MVHealth is recognized by Design Week (beating Apple), Veuve Clicquot, and IF Design Awards.
2020
Tenuto 2 & Crescendo 2 Launch: The Tenuto 2 and Crescendo 2 devices are officially released.
1M+ App Downloads: The MVHealth companion application reaches over one million downloads.
Awards: MVHealth receives Virgin Startups, Euro Product Design, LUXLife, Disruption50, Great British Entrepreneur, Welp, and The Escape100 awards.
2021
Tenuto Mini, Legato, Molto Launch: MVHealth significantly expands its product line with the launch of Tenuto Mini, Legato, and Molto devices.
Series A Funding Round: MVHealth secures $9.6m in Series A funding with a PMV of $36m.
Awards: MVHealth is recognized as a Top 10 Deeptech company and a Top Product Design Company in the UK.
2022
FSA/HSA Eligible: MVHealth devices become eligible for Flexible Spending Account (FSA) and Health Savings Account (HSA) spending.
Crescendo FSAD Study Published: A clinical study demonstrating the effectiveness of Crescendo for Female Sexual Arousal Disorder (FSAD) is published.
Endorsed by Mayo Clinic: MVHealth receives an endorsement from the Mayo Clinic.
Member of CHPA & Advamed: MVHealth becomes a member of the Consumer Healthcare Products Association (CHPA) and AdvaMed (Advanced Medical Technology Association).
Awards: MVHealth receives Dezeen, UX Design, World Future, Muse Design, and Good Design awards.
2023
Firmo & Sotto Prototypes: Development begins for the Firmo and Sotto devices, targeting menopause symptoms and period pain/mastitis respectively.
Legato FSAD and Tenuto Mini ED Studies Published: Clinical studies are published supporting the use of Legato for FSAD and Tenuto Mini for ED.
Awards: MVHealth receives Bold IV, Impact Fifty, Titan, London Design, and DNA Paris Design awards.
2024 (Upcoming)
Further development and potential launch of Firmo and Sotto devices.
Continued focus on research, development, and market expansion.
Pursuing full CMS reimbursement.
Ongoing Throughout the Decade:
Research, Development & Manufacturing: Continuous efforts in new product development and updates to existing products.
Regulatory & Compliance Approval: Obtaining necessary approvals such as FDA and CE for their devices.
Clinical Trials & Paper Publications: Conducting clinical studies and publishing findings in peer-reviewed journals.
Key Opinion Leader Onboarding & Endorsement: Building relationships with and securing endorsements from leading clinicians.
User Feedback & Efficacy Establishment: Gathering user feedback and establishing the efficacy of their devices.
Brand Awareness & Market Presence: Increasing brand recognition and expanding their presence in the market through direct sales, clinics, and hospitals.
IP Portfolio Development: Continuously expanding their patent and trademark portfolio.
Brand Credibility Building: Establishing trust through high efficacy, KOL endorsements, and user satisfaction.
Large-scale Nationwide Marketing & Trade Exhibitions: Engaging in significant marketing efforts and participating in industry events.
Reimbursement Efforts: Actively working towards securing reimbursement for their devices.
Building Strategic Partnerships: Collaborating with large corporates and healthcare companies.
